Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Interferon signaling and treatment outcome in chronic hepatitis C.

Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH.

Proc Natl Acad Sci U S A. 2008 May 13;105(19):7034-9. doi: 10.1073/pnas.0707882105.

2.

A fresh look at interferon-alpha signaling and treatment outcomes in chronic hepatitis C.

Bellecave P, Moradpour D.

Hepatology. 2008 Oct;48(4):1330-3. doi: 10.1002/hep.22571.

PMID:
18821612
3.

Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection.

Lau DT, Negash A, Chen J, Crochet N, Sinha M, Zhang Y, Guedj J, Holder S, Saito T, Lemon SM, Luxon BA, Perelson AS, Gale M Jr.

Gastroenterology. 2013 Feb;144(2):402-413.e12. doi: 10.1053/j.gastro.2012.10.044.

4.

Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.

Dill MT, Makowska Z, Duong FH, Merkofer F, Filipowicz M, Baumert TF, Tornillo L, Terracciano L, Heim MH.

Gastroenterology. 2012 Sep;143(3):777-86.e1-6. doi: 10.1053/j.gastro.2012.05.044.

PMID:
22677194
5.

Defective hepatic response to interferon and activation of suppressor of cytokine signaling 3 in chronic hepatitis C.

Huang Y, Feld JJ, Sapp RK, Nanda S, Lin JH, Blatt LM, Fried MW, Murthy K, Liang TJ.

Gastroenterology. 2007 Feb;132(2):733-44.

6.

Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race.

He XS, Ji X, Hale MB, Cheung R, Ahmed A, Guo Y, Nolan GP, Pfeffer LM, Wright TL, Risch N, Tibshirani R, Greenberg HB.

Hepatology. 2006 Aug;44(2):352-9.

PMID:
16871572
7.

Hepatic metallothionein expression in chronic hepatitis C virus infection is IFNL3 genotype-dependent.

O'Connor KS, Parnell G, Patrick E, Ahlenstiel G, Suppiah V, van der Poorten D, Read SA, Leung R, Douglas MW, Yang JY, Stewart GJ, Liddle C, George J, Booth DR.

Genes Immun. 2014 Mar;15(2):88-94. doi: 10.1038/gene.2013.66.

PMID:
24335707
8.

Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.

Plumlee CR, Lazaro CA, Fausto N, Polyak SJ.

Virol J. 2005 Dec 2;2:89.

9.

Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.

Poynard T, Marcellin P, Bissery A, Myers RP, Moussalli J, Degos F, Dhumeaux D, Riachi G, Bronowicki JP, Brissot P, Buffet C, Serfaty L, Naveau S, Sogni P, Beaugrand M, Gayno S, Larrey D, Samuel D, Eugene C, Pol S, Bedossa P, Daurat V, Chaumet-Riffaud P; GER-CYT-RIBANON group..

J Viral Hepat. 2003 May;10(3):197-204.

PMID:
12753338
10.
11.

Interferon-β and interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo.

Makowska Z, Duong FH, Trincucci G, Tough DF, Heim MH.

Hepatology. 2011 Apr;53(4):1154-63. doi: 10.1002/hep.24189.

PMID:
21480323
12.

Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.

Bautista D, Bermúdez-Silva FJ, Lasarte JJ, Rodriguez-Fonseca F, Baixeras E.

J Pathol. 2007 Nov;213(3):347-55.

PMID:
17940994
13.

Interferon alpha induced intrahepatic pSTAT1 inversely correlate with serum HCV RNA levels in chronic HCV infection.

Gunduz F, Mallikarjun C, Balart LA, Dash S.

Exp Mol Pathol. 2014 Feb;96(1):36-41. doi: 10.1016/j.yexmp.2013.10.016.

14.

IFI35, mir-99a and HCV genotype to predict sustained virological response to pegylated-interferon plus ribavirin in chronic hepatitis C.

Estrabaud E, Appourchaux K, Bièche I, Carrat F, Lapalus M, Lada O, Martinot-Peignoux M, Boyer N, Marcellin P, Vidaud M, Asselah T.

PLoS One. 2015 Apr 6;10(4):e0121395. doi: 10.1371/journal.pone.0121395.

15.

Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.

Asahina Y, Izumi N, Umeda N, Hosokawa T, Ueda K, Doi F, Tsuchiya K, Nakanishi H, Matsunaga K, Kitamura T, Kurosaki M, Uchihara M, Higaki M, Miyake S.

J Viral Hepat. 2007 Jun;14(6):396-403.

PMID:
17501760
16.

Pegylated IFN-α regulates hepatic gene expression through transient Jak/STAT activation.

Dill MT, Makowska Z, Trincucci G, Gruber AJ, Vogt JE, Filipowicz M, Calabrese D, Krol I, Lau DT, Terracciano L, van Nimwegen E, Roth V, Heim MH.

J Clin Invest. 2014 Apr;124(4):1568-81. doi: 10.1172/JCI70408.

19.

Enhancing the response to interferon-alpha.

Begemann F, Jablonowski H.

J Clin Virol. 1999 Jun;13(1-2):1-7.

PMID:
10405886
20.

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

Teuber G, Berg T, Hoffmann RM, Leifeld L, Lafrenz M, Spengler U, Pape GR, Hopf U, Zeuzem S.

Digestion. 2000;61(2):90-7.

PMID:
10705172
Items per page

Supplemental Content

Support Center